Pattrawut S / Shutterstock.com
The English Court of Appeal has ruled in favour of Eli Lilly, finding that a patent covering its blockbuster lung drug Alimta (pemetrexed disodium) would be infringed by a product proposed by Actavis, now Allergan.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Actavis, Allergan, Alimta, English Court of Appeal